Agenus UK Limited
Agenus, Inc. https://www.agenusbio.com is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit cancer patients. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, Agenus' cancer vaccine programme includes three proprietary platforms focused on individualised and off-the-shelf vaccines uniquely designed for each patient. Agenus' broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants work in combination to provide the opportunity to create best-in-class therapeutic regimens.